SWK (SWKH) Q4 2024 earnings summary

Executive summary

• Fourth quarter 2024 GAAP net income rose to $5.9 million from $2.8 million in Q4 2023, with adjusted non-GAAP net income at $6.6 million, up from $2.8 million year-over-year.

• Total revenue for Q4 2024 increased 25% to $12.4 million, driven by higher finance receivables and pharmaceutical development segment revenues.

• Monetized performing royalty portfolio for $51.3 million in March 2025, with a dividend anticipated upon closing the larger transaction.

• Ongoing stock buyback program and plans to declare a dividend following royalty monetization.

• $44 million was deployed into yielding finance receivables to life science companies, and three finance receivables were repaid at premiums to GAAP carrying value.

Financial highlights

• Q4 2024 GAAP net income: $5.9 million ($0.48/diluted share) vs. $2.8 million ($0.23/diluted share) in Q4 2023.

• Q4 2024 non-GAAP adjusted net income: $6.6 million ($0.54/share); finance receivables segment adjusted non-GAAP net income: $6.2 million, up from $3.7 million.

• Q4 2024 total revenue: $12.4 million, up from $9.9 million in Q4 2023; finance receivables segment revenue up 11.6% to $10.3 million.

• Book value per share as of Dec 31, 2024: GAAP $23.45 (up 5%), non-GAAP tangible $21.15 (up 8.3%).

• Operating expenses decreased to $6.6 million from $6.8 million year-over-year.

Outlook and guidance

• Anticipates declaring a dividend upon closing of the final royalty monetization transaction, expected within two weeks of the report.

• Entering 2025 with a healthy loan portfolio yielding in the mid-teens and over $30 million in cash, expected to rise to nearly $70 million after closing royalty sale and FX hedge.

• Continued growth expected for Mod3 Pharma (CDMO division) in 2025, aiming for unsubsidized profitability by year-end.

• Management highlights improved loan portfolio risk scoring and ongoing value return to shareholders.